U.S. drug regulators signaled on April 29 that they may authorize COVID-19 vaccines for young children in June.
The Food and Drug Administration (FDA) said it plans to convene its expert advisory panel, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), to consider updates to the Moderna and Pfizer emergency use authorizations (EUAs).